Proton-pump inhibitor
| Proton-pump inhibitor | |
|---|---|
| Drug class | |
General structure of a proton-pump inhibitor | |
| Class identifiers | |
| Use | Reduction of gastric acid production |
| ATC code | A02BC |
| Mechanism of action | Enzyme inhibitor |
| Biological target | H+/K+ ATPase |
| Clinical data | |
| Drugs.com | Drug Classes |
| WebMD | MedicineNet |
| External links | |
| MeSH | D054328 |
| Legal status | |
| In Wikidata | |
Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump. The body eventually synthesizes new proton pumps to replace the irreversibly inhibited ones—a process driven by normal cellular turnover, which gradually restores acid production.
Proton-pump inhibitors have largely superseded the H2-receptor antagonists, a group of medications with similar effects but a different mode of action, and heavy use of antacids. Potassium-competitive acid blockers (PCABs) have entered the market since the 2010s.
PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines, omeprazole being the specific listed example.